hydrochloride.

Hereinafter, the embodiment of the present disclosure is described.

[0007a]

In one aspect, the present disclosure refers to a pharmaceutical composition comprising 0.0005 w/v% or more and 0.05 w/v% or less of glucose, a non-ionic surfactant and 0.0005 w/v% or more and 0.01 w/v% or less of an alkyldiaminoethylglycine hydrochloride.

[0007b]

In another aspect, the present disclosure refers to a pharmaceutical composition comprising:

0.005 w/v% of glucose,

0.01 w/v% of a non-ionic surfactant, and

0.0025 w/v% of an alkyldiaminoethylglycine hydrochloride.

[0008]

[1] A pharmaceutical composition comprising 0.0005 w/v% or more and 0.05 w/v% or less of glucose, a non-ionic surfactant and an alkyldiaminoethylglycine hydrochloride.

[2] The pharmaceutical composition according to the above [1], comprising 0.0005 w/v% or more and 0.01 w/v% or less of the glucose.

[3] The pharmaceutical composition according to the above [1] or [2], comprising 0.002 w/v% or more and 0.01 w/v% or less of the glucose.

[4] The pharmaceutical composition according to any one of the above [1] to [3], wherein the non-ionic surfactant is one or more non-ionic surfactants selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan long-chain fatty acid monoester,

polyethylene glycol long-chain fatty acid monoester and polyoxyethylene-polyoxypropylene block copolymer.

[5] The pharmaceutical composition according to any one of the above [1] to [4], comprising 0.001 w/v% or more and 0.5 w/v% or less of the non-ionic surfactant.

[6] The pharmaceutical composition according to any one of the above [1] to [4], wherein a concentration of the non-ionic surfactant is 0.005 w/v% or more and 0.3 w/v% or less.

[7] The pharmaceutical composition according to the above [4], wherein the polyoxyethylene hydrogenated castor oil is polyoxyethylene hydrogenated castor oil 60.

[8] The pharmaceutical composition according to any one of

agent,

wherein pH is 6.5 or more and 8.0 or less.

[44] A pharmaceutical composition comprising:

0.005 w/v% of glucose,

0.01 w/v% of a non-ionic surfactant, and

0.0025 w/v% of an alkyldiaminoethylglycine hydrochloride.

[45] The pharmaceutical composition according to any one of the above [1] to [44], wherein the pharmaceutical composition is ophthalmic.

[46] The pharmaceutical composition according to any one of the above [1] to [45], wherein the pharmaceutical composition is an aqueous liquid composition.

[47] The pharmaceutical composition according to any one of the above [1] to [46], wherein the pharmaceutical composition is an ophthalmic solution.

[48] Use of 0.0005 w/v% or more and 0.05 w/v% or less of glucose, a non-ionic surfactant and an alkyldiaminoethylglycine hydrochloride for improving storage of a pharmaceutical composition.

[49] Use of 0.0005 w/v% or more and 0.05 w/v% or less of glucose, a non-ionic surfactant and an alkyldiaminoethylglycine hydrochloride for producing a pharmaceutical composition excellent in storage stability.

[50] A method for improving storage stability of a pharmaceutical composition,

wherein the pharmaceutical composition comprises 0.0005 w/v% or more and 0.01 w/v% or less of glucose,

the method comprising the step of mixing a non-ionic surfactant and an alkyldiaminoethylglycine hydrochloride in the pharmaceutical composition.

CLAIMS

1. A pharmaceutical composition comprising 0.0005 w/v% or more and 0.05 w/v% or less of glucose, a non-ionic surfactant and 0.0005 w/v% or more and 0.01 w/v% or less of an alkyldiaminoethylglycine hydrochloride.

2. The pharmaceutical composition according to claim 1, comprising 0.0005 w/v% or more and 0.01 w/v% or less of the glucose.

3. The pharmaceutical composition according to claim 1 or 2, wherein the non-ionic surfactant is one or more non-ionic surfactants selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan long-chain fatty acid monoester, polyethylene glycol long-chain fatty acid monoester and polyoxyethylene-polyoxypropylene block copolymer.

4. The pharmaceutical composition according to any one of claims 1 to 3, comprising 0.001 w/v% or more and 0.5 w/v% or less of the non-ionic surfactant.

5. The pharmaceutical composition according to any one of claims 1 to 4, comprising:

0.002 w/v% or more and 0.01 w/v% or less of the glucose,

0.005 w/v% or more and 0.05 w/v% or less of the non-ionic surfactant, and

0.001 w/v% or more and 0.005 w/v% or less of the alkyldiaminoethylglycine hydrochloride.

6. The pharmaceutical composition according to any one of claims 1 to 5, further comprising an amino acid.

7. The pharmaceutical composition according to claim 6, wherein the amino acid is taurine.

8. The pharmaceutical composition according to claim 6 or 7, comprising 0.01 w/v% or more and 1.0 w/v% or less of the amino acid.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein pH is 5.0 or more and 8.5 or less.

10. A pharmaceutical composition comprising:

0.005 w/v% of glucose,

0.01 w/v% of a non-ionic surfactant, and

0.0025 w/v% of an alkyldiaminoethylglycine hydrochloride.